AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

benzinga.com/analyst-stock-ratings/upgrades/25/06/45778542/anaptysbios-arthritis-drug-matches-top-therapies-in-phase-2-trial-analyst-sees-tur

AnaptysBio, Inc. (NASDAQ:ANAB) on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for rheumatoid arthritis.
In the 424-patient 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low…

This story appeared on benzinga.com, 2025-06-04 18:23:16.
The Entire Business World on a Single Page. Free to Use →